horizon therapeutics public limited company

In February of 2017, Horizon launched the RAREis program aimed at elevating the voices, faces and experiences of people living with rare diseases, as well as highlight programs and resources for the rare disease community. The Global Advocate Grant program launched in 2022 to provide critical financial assistance and build equity for the rare disease community by fostering growth for advocacy organizations around the world. The RAREis Global Advocate Grant is part of Horizon's RAREis program, which is committed to improving the experience of living with a rare disease, by providing support to many organizations that offer crucial programs and services for people living with rare diseases. Recurrent Respiratory Papillomatosis FoundationĪpplications are evaluated based on the organization's work to support the rare disease community and how the grant would further their ability to deliver on their missions and goals.

Paroxysmal Nocturnal Hemoglobinuria Ukraine Philippine Society for Orphan Disorders, Inc. Progressive Familial intrahepatic Cholestasis Network

Northern Ireland Rare Disease Partnership NF Patients United - Global Network of Neurofibromatosis Patient Organizations International Patient Organisation for Primary Immunodeficiencies Hypertrophic Olivary Degeneration Association Eight of the advocacy groups are recipients again this year, enabling continued programming from 2022.Īssociazione Italiana Sindrome di Beckwith-Wiedemann ODVĪssociazione Sindrome di Noonan e RASopatie ODVīrazilian Association of Prader-Willi Syndromeīulgarian Society of the Patients with PH The 50 organizations awarded the grant in 2023 represent 12 countries and focus on supporting 40 different rare diseases. Horizon received nearly 190 applications, from 33 countries, representing more than 180 different rare diseases. The 2023 RAREis Global Advocate Grant program was announced in February during Rare Disease Day. We find great meaning and purpose in this opportunity to help many different organizations - none of whom operate within any of the disease areas where Horizon makes medicines available - advance their mission.'

'We learn from every rare disease organization we interact with and are inspired by the diversity of initiatives advancing education, treatments and more. 'At Horizon, our inclusive approach to supporting patient advocacy groups helps these organizations address the most critical needs affecting their rare disease community,' said Matt Flesch, vice president, communications and patient advocacy, Horizon. These rare disease patient advocacy organizations will receive a one-time grant of $5,000 to establish new programs, develop educational resources and expand their current offerings to support their disease communities. Horizon Therapeutics plc (Nasdaq: HZNP) today announced the 50 awardees from around the world selected to receive the 2023 RAREis Global Advocate Grant.

Horizon therapeutics public limited company